急性髓系白血病患者骨髓溶血磷脂酰胆碱酰基转移酶1的表达分析

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (886 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的: 探讨急性髓系白血病（acute myeloid leukemia, AML）患者骨髓中溶血磷脂酰胆碱酰基转移酶1（lysophosphatidylcholine acyltransferase 1, LPCAT1）的表达和临床意义。方法: 应用实时定量PCR技术检测60例不同临床分型的AML患者和27例健康对照骨髓标本LPCAT1 mRNA的表达。结果: 与对照组相比,AML患者LPCAT1 mRNA的表达水平显著降低（P<0.001）。60例AML患者中27例（45％）存在LPCAT1 mRNA低表达,而27例对照均未见LPCAT1 mRNA低表达改变,差异有统计学意义（χ2=17.618,P<0.001）。LPCAT1 mRNA低表达与年龄、性别、白细胞计数、血小板计数、血红蛋白、FAB分型及核型危险分级等均无临床相关性（P>0.05）。LPCAT1 mRNA区分AML患者的受试者工作特征（ROC）曲线下面积为0.896（95% CI:0.825~0.967,P<0.001）,LPCAT1 mRNA表达的截断值为0.173时,敏感性和特异性分别为88.3%和81.5%。结论: LPCAT1低表达是AML中的常见分子事件,或可用于AML辅助诊断。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈芹1
	徐子浚1
	林江1
	钱军2
	钱炜3

关键词 ：急性髓系白血病, 溶血磷脂酰胆碱酰基转移酶1, 实时定量PCR, 骨髓, 受试者工作特征曲线, 生物标志物

Abstract：Objective:To explore the expression status of lysophosphatidylcholine acyltransferase 1 (LPCAT1) gene and its clinical significance in patients with acute myeloid leukemia (AML). Methods:Quantitative realtime PCR was used to examine the LPCAT1 mRNA expression in bone marrow samples from 60 primary AML patients and 27 healthy donors. Results: LPCAT1 mRNA expression was significant lower in AML than controls(P<0.001). LPCAT1 mRNA lowexpression was found in 27 (45%) of 60 AML cases but none in the 27 controls, the difference was statistically significant (χ2=17.618,P<0.001).There was no correlation between the lowexpression of LPCAT1 mRNA with the age, sex, white blood cell count, platelet count, hemoglobin concentration, FAB subtypes and AML karyotypic groups (P>0.05). The receiver operating characteristic (ROC) curve revealed LPCAT1 mRNA expression might serve as a potential diagnostic marker for differentiating AML from controls with an area under the ROC curve of 0.896 (95% CI:0.825~0.967, P<0.001). At the cutoff value of 0.173 of LPCAT1 mRNA expression, the sensitivity and the specificity were 88.3% and 81.5%, respectively.Conclusion: LPCAT1 lowexpression is a frequent molecular event in AML, and it may be used to assist the diagnosis of AML.

收稿日期: 2021-08-20

基金资助:国家自然科学基金资助项目（81970118）；江苏省青年医学人才项目（QNRC2016449）；江苏省医学创新团队项目（CXTDB2017002）；镇江血液学临床研究中心项目（SS2018009）

通讯作者: 钱军（通讯作者）,主任医师,博士生导师,E-mail: qianjun0007@hotmail.com；钱炜（通讯作者）,主任医师,博士生导师,E-mail: dwqian@yahoo.com

作者简介: 陈芹（1983—）,女,硕士研究生

引用本文:

陈芹1,徐子浚1,林江1,钱军2,钱炜3. 急性髓系白血病患者骨髓溶血磷脂酰胆碱酰基转移酶1的表达分析[J]. 江苏大学学报:医学版, 2022, 22(1): 50-53. CHEN Qin1, XU Zijun1, LIN Jiang1, QIAN Jun2, QIAN Wei3.

Expression analysis of lysophosphatidylcholine acyltransferase 1 gene in patients with acute myeloid leukemia

. Journal of Jiangsu University(Medicine Edition), 2022, 22(1): 50-53.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2022/V22/I1/50

［1］Santos CR, Schulze A. Lipid metabolism in cancer［J］. FEBS J, 2012, 279 (15): 2610-2623.

［2］Grupp K, Sanader S, Sirma H, et al. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers［J］. Mol Oncol, 2013, 7(6): 1001-1011.

［3］Zhou X, Lawrence TJ, He Z, et al. The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer［J］. Exp Mol Pathol, 2012, 92(1): 105-110.

［4］ShidaSakazume T, EndoSakamoto Y, Unozawa M, et al. Lysophosphatidylcholine acyltransferase 1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of plateletactivating factor［J］. PLoS One, 2015, 10(3): e0120143.

［5］Morita Y, Sakaguchi T, Ikegami K, et al. Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression［J］. J Hepatol, 2013, 59(2): 292-299.

［6］Lebok P, von Hassel A, Meiners J, et al. Upregulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer［J］. Aging (Albany NY), 2019, 11(18): 7796-7804.

［7］Abdelzaher E, Mostafa MF. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence［J］. Tumour Biol, 2015, 36(7): 5473-5483.

［8］Wei C, Dong X, Lu H, et al. LPCAT1 promotes brain metastasis of lung adenocarcinoma by upregulating PI3K/AKT/MYC pathway［J］. J Exp Clin Cancer Res, 2019, 38(1): 95.

［9］Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the FrenchAmericanBritish Cooperative Group［J］. Ann Intern Med, 1985, 103(4): 620-625.

［10］Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms［J］. Blood, 2002, 100(7): 2292-2302.

［11］陈星星,钱军,林江,等.急性髓系白血病CTNNA1基因的表达及临床意义［J］.江苏大学学报（医学版）,2014, 24(1): 52-55, 58.

［12］Wang K, Wu Z, Si Y, et al. Identification of LPCAT1 expression as a potential prognostic biomarker guiding treatment choice in acute myeloid leukemia［J］. Oncol Lett, 2021, 21(2): 105.

［13］Luo X, Xu L, Wu X, et al. Decreased SATB1 expression promotes AML cell proliferation through NFκB activation［J］. Cancer Cell Int, 2019, 19: 134.

［14］ZareAbdollahi D, Safari S, Movafagh A, et al. Intact expression status of RASSF1A in acute myeloid leukemia［J］. Med Oncol, 2014, 31(1): 770.

［15］Pietrzak J, Mirowski M, Jeleń A, et al. Decreased MMP1 gene expression in acute myeloid leukaemia［J］. Mol Biol Rep, 2019, 46(2): 2293-2298.